CRISPR Therapeutics AG Live Stock Price Today, Share Analysis and Chart

Name: CRISPR Therapeutics AG: Is Infosys Ltd. worth buying?
Item: CRISPR Therapeutics AG
Rating: 1.62491675
Author: Trendlyne DVM scores

about

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revol...

58.78 2.28 (4.04%)

25.10% Fall from 52W High

1.3M

XNAS Volume

XNAS 09 Mar, 2026 5:30 PM (EDT)

Board Meeting

The next board meeting for CRISPR Therapeutics AG is on 11 Mar 2026 for the purpose of CRISPR Therapeutics AG Annual Report for 2025 See details

Not Eligible

Expensive Valuation

8.7 / 100

Technically Neutral

56.3 / 100

1Yr Price target upside is 45%

23 analysts

CRISPR Therapeutics AG Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

CRISPR Therapeutics AG Live Stock Price Today, Share Analysis and Chart

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revol...

25.10% Fall from 52W High

SWOT Analysis

CRISPR Therapeutics AG Live Price Chart